Filing Flows › Comparisons › PRCT vs ARAY
Procept BioRobotics vs Accuray: PRCT and ARAY compared
Procept BioRobotics is the larger company: $98.3M of revenue in its latest quarter (Q3 2026) against $86.5M for Accuray (Q1 FY27). Procept BioRobotics is growing faster (+18% against -8% a year earlier). Procept BioRobotics is more profitable, with an operating margin of -27.9% against -42.2%.
Where the money goes: PRCT and ARAY
Procept BioRobotics (PRCT) · Q3 2026
Procept BioRobotics, Q3 2026: revenue $98.3M (+18% year over year), operating margin -27.9%, net loss $26.5M, operating cash flow −$9.0M. The chart follows the revenue to costs, profit and cash.
Accuray (ARAY) · Q1 FY27
Accuray, Q1 FY27: revenue $86.5M (-8% year over year), operating margin -42.2%, net earnings $10.1M, operating cash flow −$3.8M. The chart follows the revenue to costs, profit and cash.
| Procept BioRobotics (PRCT) | Accuray (ARAY) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q1 FY27 |
| Revenue | $98.3M | $86.5M |
| Revenue growth, Y/Y | +18% | -8% |
| Operating margin | -27.9% | -42.2% |
| Net earnings | −$26.5M | $10.1M |
| Net margin | -27.0% | 11.7% |
| Operating cash flow | −$9.0M | −$3.8M |
| Market value | $1.1B | — |
| Analysts’ mean target | $22.58 | — |
Where the revenue comes from
Accuray
- Service: $59.2M (68%)
- Product: $27.3M (32%)
Questions
Which is bigger, Procept BioRobotics or Accuray?
Procept BioRobotics is the larger company: $98.3M of revenue in its latest quarter (Q3 2026) against $86.5M for Accuray (Q1 FY27).
Is Procept BioRobotics or Accuray growing faster?
Procept BioRobotics is growing faster (+18% against -8% a year earlier).
Which is more profitable, Procept BioRobotics or Accuray?
Procept BioRobotics is more profitable, with an operating margin of -27.9% against -42.2%.
More: Procept BioRobotics earnings · how Procept BioRobotics makes money · Accuray earnings · how Accuray makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Nov 6, 2026). Fiscal quarters can end on different dates. Not investment advice.